Practical checks for telehealth platforms and 503A pharmacies, with a California overlay On September 18, 2026, FDA issued a warning letter to Empower Clinic Services, LLC dba Empower Pharmacy. In addressing compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin products, FDA describe...
Blog
The DEA Telemedicine Cliff Is Back: What Telehealth Prescribers Should Do Before December 31, 2026
For nearly six years, telehealth companies have prescribed controlled substances without an in-person visit under a series of temporary DEA “flexibilities” that began during the COVID-19 public health emergency. That arrangement has an end date: December 31, 2026. And this time, the permanent rep...
Patient Testimonials for Compounded Drugs: For compounding pharmacies, outsourcing facilities, prescribers, telehealth platforms, and marketing partners
Patient testimonials can be useful educational and marketing content, but testimonials about compounded drugs are regulated advertising.
FDA Clarifies Compounding Policies as GLP-1 Drug Supply Begins to Stabilize
FDA has issued a new reminder to compounders regarding the legal limits on compounding GLP-1-related drugs, including products involving semaglutide and tirzepatide, as the national supply of these medications begins to stabilize. The April 1, 2026 statement is significant for both traditional c...
The FDA's Peptide Reclassification: What's Coming, What It Means, and Why Compounding Pharmacies Should Pay Attention
The FDA's Peptide Reclassification: What's Coming, What It Means, and Why Compounding Pharmacies Should Pay Attention Published: March 12, 2026 This article is for informational purposes only and does not constitute legal advice. Consult a licensed attorney for guidance specific to your practic...
Educational Webinars, Videos, Presentations: How to Provide Compliant and Valuable Educational Content to Providers
Compounding pharmacies producing and distributing educational videos to healthcare providers on the benefits and uses of specific compounded drugs face a regulatory minefield of compliance considerations. Understanding these considerations can help pharmacies remain compliant with federal and state regulations while providing valuable educational content.
Tirzepatide Compounding Update
The FDA has stated that it does not intend to take action against compounders for violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) arising from conditions that depend on tirzepatide's inclusion on the FDA drug shortage list. Compounding pharmacies should still exercise their own ...